anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The diagnostic criteria of AECOPD is defined in global initiative for chronic obstructive lung disease (GOLD 2016). According to the efficacy of systemic hormone therapy during hospitalization, they were divided into treatment success group and treatment failure group. Definition of systemic glucocorticoid treatment failure during hospitalization is (Reference: Crisafulli E, Torres A, Huerta A, et al. COPD, 2016, 13(1): 82-92): The following occurs from the 2nd to the 7th day after admission Situation: ①Need to receive mechanical ventilation treatment or need to be admitted to the ICU due to illness; ②72 hours after the initial anti-infective treatment, clinical signs of infection persist and need to change antibiotic treatment; ③Death from any cause.
PROBLEM TO BE SOLVED: To obtain a hair-conditioning agent remarkably improved in the dispersibility of an inorganic pigment in the product without deteriorating the conditioning effect and also excellent in stability by kneading the inorganic pigment with specific components. SOLUTION: This hair-conditioning agent contains a treated product obtained by kneading an inorganic pigment (in an amount of 0.01-5wt.%) with components comprising a cationic surfactant and a polyhydric alcohol. The inorganic pigment is preferably a colored pigment. The weight ratio of the polyhydric alcohol to the inorganic pigment in the treated product is preferably 0.1-10. The cationic surfactant is preferably a quaternary ammonium salt, and contained in an amount of 0.01-5% in the kneaded product. The polyhydric alcohol includes 1,3- butylene glycol and propylene glycol, and contained in an amount of approximately 0.01-10% in the kneaded product.
Single centre, physiological crossover clinical trial in 40 patients in the immediate postoperative period after lung resection, equipped with a NAVA catheter to monitor diaphragm electrical activity (EAdi) and assess the effects that HFNC have on the respiratory drive and work of breathing as compared to conventional facemask oxygen therapy. Once in the postoperative care unit (PACU) and 1) after recovery from anaesthesia, 2) cardiorespiratory stable and 3) pain-free (see below), the intervention will start. The study will assess the effect of HFNC and oxygen via face mask on EAdi and diaphragm function, as measured by ultrasonography. HFNC and oxygen via face mask order will be randomized in a sequence (A-B or B-A) with the aid of a website (www.randomization.com). Each intervention will last for 30 minutes. The oxygen-inspired fraction (FiO2) will be adjusted to maintain a pulse oximetry (SpO2) between \>92%. In the case of the high-flow nasal cannula, the study will be carried out with a flow of 50 L/min.

EAdi signal will be continuously monitored and its signal later exported to a laptop for further analysis. At the end of the 30-minute period, a blood sample will be obtained for gas analysis from the arterial line and the investigators will perform a diaphragm ultrasonography. Ultrasonography will consist of measurement of diaphragm thickness and thickening on the right side during quiet breathing and diaphragmatic excursion on both sides.
1. A combination of alpha-tocopherol and riluzole or of a pharmaceutically acceptable salt thereof. 2. The composition according to claim 1 wherein 10 to 400 parts by weight of riluzole are used per 250 to 4000 parts by weight of alpha-tocopherol. 3. The composition according to claim 1 or 2 as a combined preparation wherein the combination for simultaneous, separate or spaced out over time using. 4. The composition according to one of claims 1-3 for the treatment of amyotrophic lateral sclerosis. 5. Use of riluzole and obtaining a combination according to claim 1. 6. A pharmaceutical composition, consisting of combination according to claim 1 in the pure state or in the presence of any compatible and pharmaceutically acceptable diluent or adjuvant.
The invention discloses an anti-CLL 1 single domain antibody and application thereof. The invention specifically discloses a single domain antibody with an amino acid sequence of SEQ ID No. 1. The single-domain antibody provided by the invention has high affinity, can well specifically target CLL1 positive cells, and can be applied to detection of CLL1 expression in bone marrow cells of AML patients. The single domain antibody of the invention can be prepared into specific antibody medicines for clinically preventing and treating CLL1 target related diseases (such as acute myelogenous leukemia, myelodysplastic syndrome or chronic myelogenous leukemia, etc.), or detection kits of CLL1 proteins, etc. The single domain antibody has stable medicine structure, small molecule, easy recombination expression and low production cost, can be used alone or used as a medicine carrying system to carry related medicines, and has very broad prospect and important significance in the fields of medicine application, clinical diagnosis and the like.
OBJECTIVES: This study aimed to evaluate the accuracy and interobserver reliability of diagnosing and subtyping gastric intestinal metaplasia (IM) among general pathologists and pathology residents at a university hospital in Thailand, focusing on the challenges in the histopathologic evaluation of gastric IM for less experienced practitioners.
METHODS: The study analyzed 44 non-neoplastic gastric biopsies, using a consensus diagnosis of gastrointestinal pathologists as the reference standard. Participants included 6 general pathologists and 9 pathology residents who assessed gastric IM and categorized its subtype (complete, incomplete, or mixed) on digital slides. After initial evaluations and receiving feedback, participants reviewed specific images of gastric IM, as agreed by experts. Following a one-month washout period, a reevaluation of the slides was conducted.
RESULTS: Diagnostic accuracy, interobserver reliability, and time taken for diagnosis improved following training, with general pathologists showing higher accuracies than residents (median accuracy of gastric IM detection: 100 % vs. 97.7 %). Increased years of experience were associated with more IM detection accuracy (p-value<0.05). However, the overall median accuracy for diagnosing incomplete IM remained lower than for complete IM (86.4 % vs. 97.7 %). After training, diagnostic errors occurred in 6 out of 44 specimens (13.6 %), reported by over 40 % of participants. Errors involved omitting 5 slides with incomplete IM and 1 with complete IM, all showing a subtle presence of IM.
CONCLUSIONS: The study highlights the diagnostic challenges in identifying incomplete gastric IM, showing notable discrepancies in accuracy and interobserver agreement. It underscores the need for better diagnostic protocols and training to enhance detection and management outcomes.
BACKGROUND: The effect of social health determinants on hernia surgery receipt is unclear. We aimed to assess the association of the social vulnerability index with the likelihood of undergoing elective and emergency hernia repair in Texas.
METHODS: This is a retrospective cohort analysis of the Texas Hospital Inpatient Discharge Public Use Data File and Texas Outpatient Surgical and Radiological Procedure Public Use Data File from 2016 to 2019. Patients ≥18 years old with inguinal or umbilical hernia were included. Social vulnerability index and urban/rural status were merged with the database at the county level. Patients were stratified based on social vulnerability index quartiles, with the lowest quartile (Q1) designated as low vulnerability, Q2 and Q3 as average, and Q4 as high vulnerability. Wilcoxon rank sum, t test, and χ2 analysis were used, as appropriate. The relative risk of undergoing surgery was calculated with subgroup sensitivity analysis.
RESULTS: Of 234,843 patients assessed, 148,139 (63.1%) underwent surgery. Compared to patients with an average social vulnerability index, the low social vulnerability index group was 36% more likely to receive surgery (relative risk: 1.36, 95% CI 1.34-1.37), whereas the high social vulnerability index group was 14% less likely to receive surgery (relative risk: 0.86, 95% CI 0.85-0.86). This remained significant after stratifying for age, sex, insurance status, ethnicity, and urban/rural status (P < .05). For emergency admissions, there was no difference in receipt of surgery by social vulnerability index.
CONCLUSION: Vulnerable patients are less likely to undergo elective surgical hernia repair, even after adjusting for demographics, insurance, and urbanicity. The social vulnerability index may be a useful indicator of social determinants of health barriers to hernia repair.
Flexibility, Toning and Balance or FTB will be used to refer to our resistive exercise comparison. As in the experimental group, participants will be asked to attend as many of the 24 in-person intervention sessions as they can, whilst also practicing the exercises remotely via video content distributed to them. The remote portion of this intervention will be asynchronous. Heart-rate will be monitored periodically to make sure the intensity of exercise is consistent with mild to moderate cardiovascular exercise as in the martial arts experimental group.
Will participate in assessments for the study (baseline and quarterly follow ups) and will complete up to 12 months of falls calendars. No intervention will be given to this group, but standard practices of care delivered by the MercyOneSM Health Network.
Stroke is a leading cause of disability. According to the comprehensive standardized prevalence estimation in 2016, 12.42 million people older than 40 years in China are currently suffering from stroke or have ever suffered from stroke. The overall prevalence rate of stroke in China was 1,596 per 100,000 people in 2016, 4.6 times higher than the rate of 345.1 per 100,000 people in 2013 and 70% of the survivors have disabilities in varying degrees. In addition to rehabilitation therapy, there is no therapeutic drugs of remarkable curative effect for the treatment of ischemic stroke patients. The latest data show that the annual recurrence rate of ischemic stroke in China is as high as 17.7%.

Allogeneic mesenchymal stem cells have been used in many clinical studies for different diseases. In addition to differentiating into multiple cell types and promoting the recovery and repair of the brain by replacing damaged cells, mesenchymal stem cells also secrete cytokines and neurotrophic factors to support and stimulate the growth of other endogenous cells. Meanwhile, mesenchymal stem cells also have anti-inflammatory and immunomodulatory functions. These characteristics of mesenchymal stem cells provide a new therapy for the treatment of stroke.
Busulfan Injection is incompatible with polycarbonate. Do not use any infusion components (syringes, filter needles, intravenous tubing, etc.) containing polycarbonate with Busulfan Injection.

Use an administration set with minimal residual hold-up volume (2 mL to 5 mL) for product administration.

Busulfan Injection is a cytotoxic drug. Follow applicable special handling and disposal procedures. Skin reactions may occur with accidental exposure. Use gloves when preparing Busulfan Injection. If Busulfan Injection or diluted Busulfan Injection solution contacts the skin or mucosa, wash the skin or mucosa thoroughly with water.

Visually inspect parenteral drug products for particulate matter and discoloration prior to administration whenever the solution and container permit. Do not use if particulate matter is seen in the Busulfan Injection vial.
The invention discloses a chitosan-monomethoxy polyethylene glycol gel delivery system and a preparation method thereof. The gel contains 2.0 to 2.5 weight percent of chitosan, 3.5 to 4.0 weight percent of monomethoxy polyethylene glycol and collagen. The gel system has temperature sensitivity, and can be kept in a liquid state at normal temperature and converted into a solid state at the temperature of 37 DEG C. The invention simultaneously discloses the preparation method of the system. The preparation method comprises the following steps of: preparing a 30 percent monomethoxy polyethylene glycol solution; preparing a chitosan solution by using acetic acid; dissolving the collagen into 0.1M sodium hydroxide; and placing the three solutions in ice bath and stirring and mixing to prepare the gel solution system. The invention also discloses a gel delivery system of a tumor necrosis factor alpha and a gel delivery system of leptin. The gel delivery systems are high in temperature sensitivity and mild in preparation conditions, and can be widely applied to the field of medicament carriers.
The SARS-CoV-2 pandemic puts an unprecedented burden on the healthcare system, specifically its healthcare providers and the resource demands for intensive care units (ICUs). To support effective care despite large case numbers, hospital operations urgently need improved decision support in early identification of patients at risk of an acute COVID-19 deterioration that requires ICU.

The investigators aim at developing a wearable-based ICU algorithm for inpatients contracted with SARS-CoV-2. Inpatients on the general ward with suspicion of COVID-19 or with confirmed SARS-CoV-2 infection will be included. The participant will be equipped with a smartwatch and wear the device throughout the hospital stay until the patient (1) is discharged home, (2) is transferred to the ICU, or (3) palliative care is initiated. The smartwatch collects several physiological parameters (e.g. heart rate, heart rate variability, respiration rate, oxygen saturation). The collected data will be used to develop an ICU prediction algorithm to detect patients at risk of an acute COVID-19 deterioration that requires ICU.
PURPOSE: A Demineralized bone particle (DBP) gel is provided to simplify preparation, to maintain gel form, and to ensure easy storage and biocompatibility. CONSTITUTION: A gel for chondrogenesis contains demineralized bone particle (DBP), pepsin, and acetic acid. The DBP is mammalian bone. The particle size of the DBP is 10-300 micrometer. The weight ratio of the DBP is 5-20 wt%. A composition for treating cartilage damage has pH 6-7.
The present invention relates to compositions, methods and uses of compounds (e.g., glatiramer acetate and glatiramer acetate related actives and products) that induce HLA-E restricted lymphocytes (e.g., HLA-E restricted CD8T cells and/or NK cells) and reduce HIV viral load in humans infected with HIV, particularly for treating HIV infection. Macaques chronically infected with SIV have been treated with glatiramer acetate. One of the animals has progressed to the AIDS stage. We injected glatiramer acetate 18mg three times a week for only 2 weeks. Surprisingly, a strong effect on viral load in response to treatment was observed. Viremia was reduced by one order of magnitude during glatiramer acetate treatment. More surprisingly, this reduction continued after cessation of treatment, which was reduced by almost two orders of magnitude in one animal. This is an important result compared to cART, since stopping cART results in a rebound of viral load within days. This reduction was associated with activation of HLA-E restricted CD8T cells, but not other classical CD8+ T cells.
To cause vision-disrupting fibrotic secondary cataract (PCO), lens epithelial cells that survive cataract surgery must migrate to the posterior of the lens capsule and differentiate into myofibroblasts. During this process, the cells become exposed to the FGF that diffuses out of the vitreous body. In normal development, such relatively high levels of FGF induce lens epithelial cells to differentiate into lens fiber cells. It has been a mystery as to how lens cells could instead undergo a mutually exclusive cell fate, namely epithelial to myofibroblast transition, in the FGF-rich environment of the posterior capsule. We and others have reported that the ability of TGFβ to induce lens cell fibrosis requires the activity of endogenous ErbBs. We show here that lens fiber-promoting levels of FGF induce desensitization of ErbB1 (EGFR) that involves its phosphorylation on threonine 669 mediated by both ERK and p38 activity. Transinhibition of ErbB1 by FGF is overcome by a time-dependent increase in ErbB1 levels induced by TGFβ, the activation of which is increased after cataract surgery. Our studies provide a rationale for why TGFβ upregulates ErbB1 in lens cells and further support the receptor as a therapeutic target for PCO.
The invention belongs to the technical field of medicines, and particularly relates to an antibiotic with small side effect and remarkable curative effect. The invention includes a tablet having components comprising: rifampicin, isoniazid, glycerol, stearic acid, papaya seeds, gardenia, black sesame, pomegranate leaves, agastache rugosus, hawthorn, orange, mung bean, ginger, rapeseed, liquorice, barbed skullcap, selfheal, andrographis paniculata, dandelion, houttuynia cordata, purslane and water. The antibiotic of the invention has small side effect and obvious curative effect. Most of the conventional antibiotics are chemically synthesized or semi-synthesized compounds, and have considerable side effects on human bodies. After long-term use, the medicine can cause irreversible damage to the body. The antibiotic of the invention is added with Chinese herbal medicine components such as common selfheal fruit-spike, heartleaf houttuynia herb and the like, and belongs to the combination of Chinese and western medicines. Not only can achieve the purpose of treating diseases, but also reduces the side effect of the medicine. The traditional Chinese medicine composition has a remarkable disease treatment effect and small side effect, and is suitable for popularization and administration in related people.
A system for determining relative operational performance in a clinical trial may include a processor, a data comparator and visualizer, and a graphical user interface. The processor filters received clinical data into multiple metric criteria to generate multiple metric data sets and filters each metric data set into a respective industry data set and a respective candidate data set. The processor then calculates statistical measures for each industry data set and candidate data set and transforms each industry data set and candidate data set based on each data set's respective statistical measures. The data comparator and visualizer compares each transformed candidate data set to the transformed industry data set for the respective metric criterion to determine a candidate percentile for each metric criterion. The graphical user interface displays the candidate percentiles for the metric criteria. A method for determining relative operational performance in a clinical trial is also described.
EPIVIR scored tablet is the preferred formulation for HIV-1–infected pediatric patients who weigh at least 14 kg and for whom a solid dosage form is appropriate. Before prescribing EPIVIR scored tablets, pediatric patients should be assessed for the ability to swallow tablets. For patients unable to safely and reliably swallow EPIVIR tablets, the oral solution formulation may be prescribed [see Warnings and Precautions (5.5)]. The recommended oral dosage of EPIVIR tablets for HIV-1–infected pediatric patients is presented in Table 1.

Oral Solution

The recommended dosage of EPIVIR oral solution in HIV-1–infected pediatric patients aged 3 months and older is 5 mg per kg taken orally twice daily or 10 mg per kg taken orally once daily (up to a maximum of 300 mg daily), administered in combination with other antiretroviral agents [see Clinical Pharmacology (12.3)]. Consider HIV-1 viral load and CD4+ cell count/percentage when selecting the dosing interval for patients initiating treatment with oral solution [see Warnings and Precautions (5.5), Clinical Pharmacology (12.3)].
Adverse events that were assessed as “severe” occurred in similar frequencies in both treatment and placebo groups, with asthenia being the most common adverse event reported as severe in both placebo and treated patients. Although the patient numbers are small, abdominal pain reported as a severe adverse event occurred in 6 treated 200 mg patients, 2 treated 100mg patients, and no placebo patients. 

Serious adverse events occurred in 39 200 mg, 7 100 mg, and 47 placebo patients participating in GL94-01 and GL95-02. However, only 3 serious adverse events were considered possibly related, 2 in the placebo group (one suicide and one patient with menomettrorhagia) and one in 200 mg (a patient with an acute psychosis). 

In the Taiwan study, serious adverse events were reported in a significantly higher proportion of patients in the placebo group than in the treatment group. In most cases, the types of serious adverse events reported were consistent with SLE flares or hospitalization for manifestations of SLE, rather than adverse effects of the study drug.
Headache, rash, pruritus and occasional gastrointestinal disturbance. An anaphylactoid-like reaction has been described. Methemoglobinemia, hemolytic anemia, renal and hepatic toxicity have been reported, usually at overdosage levels (see Error! Hyperlink reference not valid. section).

To report SUSPECTED ADVERSE REACTIONS, contact Amneal Pharmaceuticals at 1-877-835-5472 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
Participants randomized to Baduanjin intervention group receive health education plus a Baduanjin training program. The Baduanjin training program was a 16-week, instructor-led group training program that offers breathing training as a core skill.
Postnatal scanty milk secretion is a common complaint. Some physical and medicinal therapies have been proposed to enhance milk production. These therapies must be both successful and safe for both the mother and the child. In many cases, milk supply can be increased by frequent, regular milk removal, Medication to increase milk supply (galactogogues) such as domperidone.

Domperidone has been linked to maternal adverse effects in galactogogue trials and cases reported to the Food and Drug Administration include dry mouth, headache, dizziness, nausea, abdominal cramping, diarrhea, palpitations malaise, and shortness of breath. Some of these were more frequent with dosages greater than with 30 mg daily. Drug withdrawal symptoms consisting of insomnia, anxiety, and tachycardia were reported in a woman taking 80 mg of domperidone daily for 8 months as a galactogogue who abruptly tapered the dose over 3 days.